{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056256","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.481435+00:00","generated_at":"2026-06-02T06:18:58.103825+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Q32 Bio reports Q1 2024 results; cash $135.3M, pipeline on track","bullets":["Cash, equivalents, and short-term investments of $135.3M as of March 31, 2024; funding into mid-2026.","Completed enrollment in bempikibart Phase 2 alopecia areata trial; topline results expected Q4 2024.","ADX-097 renal basket Phase 2 trial to start H1 2024; initial data expected by year-end 2024.","Reverse merger with Homology Medicines closed in March 2024; concurrent $42M private placement.","Net income of $1.0M due to $15.9M gain on convertible note conversion; R&D expense $9.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056256","json":"https://secwatch.observer/filing/0000950170-24-056256.json","markdown":"https://secwatch.observer/filing/0000950170-24-056256.md","text":"https://secwatch.observer/filing/0000950170-24-056256.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000095017024056256/0000950170-24-056256-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000095017024056256/qttb-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:18:58.103825+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"de638b8f5b128432425b5892258111cb54c389f8","claim":"Q32 Bio Inc. reported the quarter ended March 31, 2024 results: net income $1.0 million, EPS $1.03 basic net income per share and ($6.33) diluted net loss per share.","evidence_excerpt":"Q32 Bio Inc. announced its financial results for the quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661998/000095017024056256/0000950170-24-056256-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"$1.0 million"},{"label":"EPS","value":"$1.03 basic net income per share and ($6.33) diluted net loss per share"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}